- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Myelofibrosis
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 May 2026 PBAC Meetings - (PDF 941.9KB)
- Public Summary Document (PSD) November 2025 May 2026 PBAC Meetings - (Word 207.8KB)
Fedratinib – November 2025 – May 2026
Fedratinib: Capsule 100 mg; Inrebic® - November 2025
Last updated
24 April 2026
